Block Grant R18HP07641

Federal Cooperative Agreement Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the Regents of the University of Michigan a $2.85 million Cooperative Agreement (CFDA 93.279, Drug Use and Addiction Research Programs) effective September 19, 2025, through July 31, 2030, to conduct a Sequential Multiple Assignment Randomized Trial (SMART) study addressing personalized treatment approaches for chronic low back pain (CLBP). The research addresses a critical...

Federal Cooperative Agreement Summary The National Institute of Neurological Disorders and Stroke awarded a $823,860 Cooperative Agreement to the University of California, Los Angeles on August 15, 2025, to conduct a pragmatic trial evaluating Emotional Awareness and Expression Therapy (EAET) for veterans with chronic pain. The project addresses a significant clinical need, as chronic pain affects approximately one-third of the veteran population and frequently co-occurs with trauma and mental...

Federal Cooperative Agreement Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Pittsburgh a $7.59 million Cooperative Agreement on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to advance understanding of chronic low back pain (CLBP) and its relationship to broader pain conditions. The research leverages existing infrastructure and cohorts from the HEAL Initiative's BACPAC Consortium, which has...

This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will provide $332,716.00 to Michigan State University to assess the feasibility of implementing manual medicine techniques in the multimodal management of chronic low back pain among veterans and service members. The research, which will be conducted from November 1, 2024, to October 31, 2026, aims to explore innovative approaches to...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...

This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA), under the FDA Research program (CFDA 93.103), provides $1,999,980 to Oregon Health & Science University (OHSU) to develop evidence-based clinical practice guidelines for the management of acute low back pain. The project aims to conduct a systematic review of the literature, derive clinical guidelines, and implement a dissemination and evaluation campaign to drive adoption of the guidelines. OHSU has...

This $556,160 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) aims to examine the efficacy of a rehabilitation approach called Rehabilitation with Exercise and Psychological Support (REPS) for patients who have undergone ACL reconstruction surgery. The REPS intervention integrates standard exercise rehabilitation with psychological support, including clinician training, patient education videos, and techniques like...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...

This $1,352,341 Project Grant award, provided by the U.S. Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, will fund a study on the comparative effectiveness of exercise, cognitive behavioral therapy, and their combination for individuals with chronic musculoskeletal pain and poor sleep. The research will be conducted by the University of Sydney in Australia, with a performance period from September 30, 2024 to September 29,...